Search clinical trials for: Rivaroxaban

Total 536 results

Bayer
Janssen Research & Development, LLC; Colorado Prevention Center

Completed

Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities (VOYAGER PAD)

Peripheral Artery Disease

Poland, Belgium, France, Spain, China, Korea, Republic of, United States, Switzerland, Estonia, Portugal, Japan, Hungary, Canada, Netherlands, Finland, Austria, United Kingdom, Germany, Czechia, Thailand, Brazil, Denmark, Italy, Russian... and more
University of Arizona

Unknown

Chlorhexidine Gluconate Versus Povidone-iodine (CHDvPI)

Vaginal Flora Imbalance
Bayer
Janssen Research & Development, LLC

Completed

Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Factor Xa Non-vitamin-K Oral Anticoagulants (NOACs) vs. Phenprocoumon (ReLoaDeD)

Atrial Fibrillation

Germany
Bayer
Janssen Research & Development, LLC

Completed

Xarelto on Prevention of Stroke and Noncentral Nervous System Systemic Embolism in Treatment-naïve Asian Patients With Non-valvular Atrial Fibrillation (XaMINA)

Atrial Fibrillation

Korea, Republic of, Taiwan
University of Pavia

Completed

ORal anticoaGulants in diAbetic and Nondiabetic Patients With nOn-valvular Atrial fibrillatioN (ORGANON) (ORGANON)

Diabetes

Italy
Onze Lieve Vrouw Hospital

Completed

Oral Anticoagulation in Hemodialysis

Atrial Fibrillation

Belgium
University Hospital Inselspital, Berne
Bayer

Completed

Rivaroxaban Hypericum Trial

Drug Interaction Study

Switzerland
Samsung Medical Center
Bayer

Unknown

Rivaroxaban in Elderly NVAF Patients With or Without Renal Impairment (XAIENT)

Renal Insufficiency | Atrial Fibrillation | Elderly | Rivaroxaban

Korea, Republic of
RWTH Aachen University
Bayer

Completed

Rivaroxaban Compared to Vitamin K Antagonist Upon Development of Cardiovascular Calcification

Atrial Fibrillation or Pulmonary Embolism | Need of Long Term Oral Anticoagulation Therapy (OAT) | Existent Coronary or Valvular Calcification, or Both and Agatston Score > 50 in at Least One Location

Germany
Ohio State University

Terminated

Statin Use in Patients With Acute VTE

Venous Thromboembolism

United States
LifeBridge Health
Janssen Scientific Affairs, LLC

Unknown

Synergistic Influence of Rivaroxaban on Inflammation and Coagulation Biomarkers in Patients With CAD and PAD on Aspirin Therapy

Coronary Artery Disease | Peripheral Artery Disease

United States
Perosphere Pharmaceuticals Inc, a wholly owned...

Completed

Phase 2 Study of Rivaroxaban Reversal by Ciraparantag as Measured by WBCT

Healthy

United States
Bayer
Janssen Scientific Affairs, LLC

Completed

Xarelto on Prevention of Stroke and Non-central Nervous System Systemic Embolism in Patients With Non-valvular Atrial Fibrillation in China: A Non-interventional Study (XASSURE)

Stroke

China
Bayer
Janssen Research & Development, LLC

Completed

Rivaroxaban vs Warfarin for SPAF in Multi-morbid Patients

Nonvalvular Atrial Fibrillation

United States
Bayer
Janssen Research & Development, LLC

Completed

Study to Compare the Effect of the Formulations (Orally Disintegrating Tablet and Film-coated Tablet) on the Bioequivalence of Drug Rivaroxaban (Xarelto) at Dose of 15 mg in Japanese Healthy Male Adult Subjects

Clinical Pharmacology

Japan
University of Novi Sad

Completed

Oral Surgery in Patients Taking Direct Oral Anticoagulants (OSDOA)

Surgery | Postoperative Hemorrhage | Anticoagulants and Bleeding Disorders | Dentoalveolar Haemorrhage

Serbia
Bayer
Janssen Research & Development, LLC

Completed

Study to Compare the Effect of the Formulations (Orally Disintegrating Tablet and Film-coated Tablet) on Bioequivalence of Drug Rivaroxaban (Xarelto) at Dose of 10 mg in Japanese Healthy Male Adult Subjects

Clinical Pharmacology

Japan
King's College Hospital NHS Trust
Bayer

Completed

Follow-up in Rivaroxaban Patients in Setting of Thromboembolism (FIRST)

Venous Thromboembolism

United Kingdom
Mayo Clinic

Terminated

Vascular Boot Warming Program After Acute Deep Vein Thrombosis (DVT) ± Pulmonary Embolism (PE)

Acute DVT of Lower Extremity

United States
King's College Hospital NHS Trust

Withdrawn

Ambulatory Blood Pressure Monitoring in Rivaroxaban Therapy

Hypotension

United Kingdom
Indiana University
Bristol-Myers Squibb; Pfizer; Janssen Pharmaceuticals

Completed

Monotherapy Anticoagulation To Expedite Home Treatment of Venous Thromboembolism (MATHVTE)

Venous Thromboembolism

United States
Jan Kochanowski University
Medical University of Warsaw

Unknown

Polish Atrial Fibrillation (POL-AF) Registry (POL-AF)

Atrial Fibrillation

Poland
Ottawa Hospital Research Institute
University of Alberta; Hamilton Health Sciences Corporation; Queen Elizabeth...

Completed

Thromboprophylaxis With Rivaroxaban In Patients With Malignancy and Central Venous Lines (TRIM-Line)

Cancer | Central Venous Catheter Thrombosis | Upper Extremity Deep Vein Thrombosis

Canada
Cardioangiologisches Centrum Bethanien

Withdrawn

Reversal Agent Use in Patients Treated With Direct Oral Anticoagulants or Vitamin K Antagonists (RADOA). Focus on New Antidots

Urgent Surgery | Severe Bleeding
Cardioangiologisches Centrum Bethanien
Goethe University; Ruhr University of Bochum; Technische Universität Dresden; University... and other collaborators

Completed

Reversal Agent Use in Patients Treated With Direct Oral Anticoagulants or Vitamin K Antagonists (RADOA)

Urgent Surgery | Severe Bleeding

Germany
Thomas Hope

Completed

Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumor

Neuroendocrine Tumor

United States
Albert Einstein Healthcare Network

Completed

Can Rivaroxaban Lead to Anticoagulation-Related Nephropathy?

Acute Kidney Injury

United States
Second Affiliated Hospital, School of Medicine,...

Unknown

Prophylactic Anticoagulation for Catheter-related Thrombosis

Venous Thrombosis Due to Central Venous Access Device (Disorder) | Prophylactic Anticoagulation | Patients With Tumor

China
The Young Investigator Group of Cardiovascular...

Completed

Comparative Study of Oral Anticoagulation in Left Ventricular Thrombi (No-LVT)

Left Ventricular Thrombosis | Anticoagulants; Increased

Egypt
The Affiliated Hospital of Qingdao University

Completed

Pharmacokinetics and Bioequivalence of Rivaroxaban Tablet in Healthy Chinese Volunteers

Healthy Subjects

China
Dr Carlo Lavalle
Istituto Nazionale per le Ricerche Cardiovascolari (INRC)

Unknown

Italian Registry In the Setting of AF Ablation With Rivaroxaban (IRIS) (IRIS)

Atrial Fibrillation

Italy
Hospital Geral Roberto Santos

Terminated

Rivaroxaban vs Warfarin in Patients With Metallic Prosthesis (RIWA)

Stroke | Valve Heart Disease | Anticoagulants and Bleeding Disorders | Prostheses and Implants

Brazil
Bayer
Janssen Scientific Affairs, LLC

Completed

Use of Direct Oral Anticoagulants in UK

Stroke

United Kingdom
University of North Carolina, Chapel Hill
National Heart, Lung, and Blood Institute (NHLBI)

Completed

The Effect of Rivaroxaban in Sickle Cell Disease

Sickle Cell Anemia | Sickle Cell-Beta0-Thalassemia

United States
Bayer
Janssen Research & Development, LLC

Completed

EINSTEIN Junior: Oral Rivaroxaban in Children With Venous Thrombosis (EINSTEIN Jr)

Venous Thromboembolism

Belgium, China, Hong Kong, United States, Switzerland, Spain, Russian Federation, Singapore, Canada, Germany, Netherlands, United Kingdom, Austria, Brazil, Israel, Italy, Mexico, Turkey, France, Australia, Finland, Hungary, Japan, Arg... and more
LiuZhou People's Hospital

Unknown

Rivaroxaban for Thromboprophylaxis in High-risk Cancer Patients With Totally Implantable Access Ports

Cancer | Rivaroxaban | Thromboprophylaxis
R&D Cardiologie
St. Antonius Hospital

Unknown

What is the Optimal antiplatElet and Anticoagulant Therapy in Patients With Oral Anticoagulation Undergoing revasculariSaTion 2. (WOEST 2)

Myocardial Infarction | Stroke | Bleeding | Acute Coronary Syndromes | Coronary Artery Diseases | Atrial Fibrillations | Heart Valve Prostheses

Belgium, Netherlands
East and North Hertfordshire NHS Trust
University of Hertfordshire

Unknown

Can Very Low Dose Rivaroxaban in Addition to Dual Antiplatelet Therapy (DAPT) Improve Thrombotic Status in Acute Coronray Syndrome (ACS) ACS (VaLiDate-R)

Acute Coronary Syndrome

United Kingdom
Florida Orthopaedic Institute
Orthopaedic Trauma Association

Unknown

Deep Vein Thrombosis Prophylaxis Adherence: Enoxaparin vs Rivaroxaban

Deep Vein Thrombosis | Venous Thromboembolism

United States
ECRI bv
Bayer; Rigshospitalet, Denmark; Cardialysis BV

Completed

Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT) (GALILEO-4D)

Cardiovascular Diseases | Thrombosis | Aortic Valve Stenosis | Heart Valve Diseases | Ventricular Outflow Obstruction

Germany, United States, Denmark, Switzerland, Netherlands, Sweden, Canada
Bayer
Janssen Research & Development, LLC

Terminated

Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes (GALILEO)

Transcatheter Aortic Valve Replacement

Belgium, France, Germany, Spain, United States, Switzerland, Canada, Austria, United Kingdom, Korea, Republic of, Denmark, Italy, Netherlands, Poland, Czechia, Sweden, Norway
Asan Medical Center

Unknown

A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism (PRIORITY)

Stomach Cancer | Hepatocellular Carcinoma | Pancreatic Cancer | Esophageal Cancer | Duodenal Cancer | Esophagogastric Junction Cancer | Cancer-associated Thrombosis | Ampulla of Vater Cancer | Malignant Gastrointestinal Stromal Tumor | Biliary Cancer (Cholangiocarcinoma, Gall Bladder Cancer)

Korea, Republic of
Duke University
Patient-Centered Outcomes Research Institute

Terminated

Comparison of Oral Anticoagulants for Extended VEnous Thromboembolism (COVET)

Venous Thromboembolism

United States
Bayer
Janssen Research & Development, LLC

Completed

Clinical Outcomes Among Non-valvular Atrial Fibrillation Patients With Renal Dysfunction (CALLIPER)

Atrial Fibrillation

United States
Ottawa Hospital Research Institute
The Ottawa Hospital

Completed

Pilot Study to Examine the Use of Rivaroxaban After Angioplasty for Critical Limb Ischemia (RIVAL-PAD)

Critical Limb Ischemia

Canada
Janssen Research & Development, LLC
Bayer

Completed

A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients (MARINER)

Heart Failure | Rheumatic Diseases | Respiratory Insufficiency | Infectious Diseases | Stroke Acute

United States, Poland, Ukraine, United Kingdom, Germany, Spain, Argentina, Belarus, Colombia, Israel, Mexico, Portugal, Bulgaria, Romania, Serbia, South Africa, Turkey, Canada, Australia, Netherlands, Denmark, Greece, Peru, Brazil, Russian... and more
Matthew Neal MD
Janssen Scientific Affairs, LLC

Completed

Utilization of TEG to Monitor Rivaroxaban Activity

Anemia | Venous Thrombosis

United States
University Hospital, Angers

Completed

Vascular CalcIfiCation and sTiffness Induced by ORal antIcoAgulation (VICTORIA)

Venous Thrombosis | Pulmonary Embolism | Permanent Atrial Fibrillation | Anticoagulation Treatment at Least > or = to 12-month

France
Ottawa Heart Institute Research Corporation
Bristol-Myers Squibb; Bayer; Boehringer Ingelheim; Heart and Stroke Foundation...

Completed

Strategy of Continued Versus Interrupted Novel Oral Anti-coagulant at Time of Device Surgery in Patients With Moderate to High Risk of Arterial Thromboembolic Events (BRUISECONTROL2)

Hematoma

Canada, Israel
Janssen Research & Development, LLC
Bayer

Completed

A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants

Neoplasms

United States, France, United Kingdom, Germany, Belgium, Bulgaria, Canada, Brazil, Russian Federation, Czechia

Search clinical trials for: Rivaroxaban

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Moldova

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations